@article{Shaw_R-2022_90396,
title = {Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial},
author = {Shaw, R. and Liu, X. and Stuart, A. and Greenland, M. and Aley, P. and Andrews, N. and Cameron, J. and Charlton, S. and Clutterbuck, E. and Collins, A. and Dejnirattisai, W. and Dinesh, T. and Faust, S. and Ferreira, D. and Finn, A. and Green, C. and Hallis, B. and Heath, P. and Hill, H. and Lambe, T. and Lazarus, R. and Libri, V. and Long, F. and Mujadidi, Y. and Plested, E. and Morey, E. and Provstgaard-Morys, S. and Ramasamy, M. and Ramsay, M. and Read, R. and Robinson, H. and Screaton, G. and Singh, N. and Turner, D. and Turner, P. and Vichos, J. and Walker, L. and White, R. and Nguyen-Van-Tam, J. and Snape, M. and Com-COV Study Group},
month = {jun},
year = {2022},
abstract = {ackgroundPriming COVID-19 vaccine schedules have been deployed at variable intervals globally, which might influence immune persistence and the relative importance of third-dose booster programmes. Here, we report exploratory analyses from the Com-COV trial, assessing the effect of 4-week versus 12-week priming intervals onreactogenicityand the persistence of immune response up to 6 months after homologous and heterologous priming schedules using the vaccines BNT162b2 (tozinameran, Pfizer/BioNTech) and ChAdOx1 nCoV-19 (AstraZeneca).},
journal = {The Lancet Respiratory Medicine},
publisher = {Elsevier},
url = {https://doi.org/10.1016/S2213-2600(22)00163-1},
}
